Discover ELF™, a simple blood test to address a complex disease.
- The Enhanced Liver Fibrosis (ELF) Test is the first routine, standardized, direct-biomarker panel for prognostic risk assessment in patients with advanced fibrosis due to NASH.
- ELF is the first and only in vitro diagnostic to be granted De Novo Marketing Authorization by the FDA for prognosis of patients with advanced fibrosis due to NASH.
- The widely studied ELF Test can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker.
"What's really scary, are the number of people who progress to cirrhosis and present for the first time when they develop a complication of cirrhosis, because our options at that point are so limited. So it's really important for us to be able to risk stratify".
Founder, Stravitz-Sanyal Institute
Learn more
